BioSpace News Archive

Encompass Health Corporation (NYSE: EHC) today issued notice for redemption of $100 million of the outstanding principal balance of its 5.75% senior notes due 2024 (the “2024 Notes”).

The ExOne Company announced a collaboration with Oak Ridge National Laboratory, the largest U.S. Department of Energy open science laboratory, to make further advancements in 3D binder jetting additive manufacturing.

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced financial results for the first quarter ended March 31, 2019.

Calyxt, Inc. (NASDAQ: CLXT), a healthy food ingredient company, announced today that its co-founder and Chief Science Officer, Dan Voytas, Ph.D., has been elected to the National Academy of Sciences (NAS) for his many contributions to the field of plant genomics, one of which is being an inventor of the TALEN® gene-editing technology.

Veeva Systems (NYSE:VEEV) will announce financial results for its fiscal first quarter which ended April 30, 2019 after market close on May 29, 2019.

Affera, Inc., a private medical device company focused on innovative cardiac arrhythmia treatment solutions, announced today its integrated platform will be highlighted in seventeen scientific sessions at the Heart Rhythm Society 2019 (HRS) meeting in San Francisco.

Intersect ENT®, Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today reported financial results for the first quarter ended March 31, 2019.

EVERFI, the leading social impact education innovator, will host its second annual Prescription Drug Safety Network (PDSN) Summit in Washington. D.C.

Diplomat Pharmacy, Inc. (NYSE: DPLO), announced today that the company’s board of directors has appointed Dave Loschinskey to serve as chief operating officer effective May 2.

Sage Therapeutics, Inc. announced that, on May 1, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 21,680 shares of its common stock, and 6,280 performance restricted stock units to six new employees under Sage’s 2016 Inducement Equity Plan.